Continuum Advisory’s Akero Therapeutics AKRO Stock Holding History

Continuum Advisory’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18	Closed	-$501	–	1664
2024 Q4	$501	Hold	18	–	–	﹤0.01%	1734
2024 Q3	$536	Buy	+18	New	+$469	﹤0.01%	1772

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Continuum Advisory's AKRO Position: Q1 2025 in Review

Continuum Advisory sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 18 shares — an estimated $501 sold.

Continuum Advisory first reported a position in AKRO in Q3 2024 and held it in 2 quarters. The position peaked at $536 in Q3 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

Continuum Advisory reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
Continuum Advisory sold 18 Akero Therapeutics shares in Q1 2025, an estimated $501.
Continuum Advisory first reported a position in Akero Therapeutics in Q3 2024 and held it in 2 quarters.
Continuum Advisory's Akero Therapeutics position peaked at $536 in Q3 2024.
240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.